Medicare to Cover Expensive Cancer Cell Therapies

The U.S. Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc (GILD.O) and Novartis AG (NOVN.S). CMS, which runs Medicare – the federal government’s health plan for Americans 65 and older – said it will cover the U.S. Food and Drug Administration-approved therapies when provided in healthcare facilities that have programs in place to track patient outcomes.

Source: https://www.reuters.com/article/us-health-medicare-cancer/medicare-to-cover-expensive-cancer-cell-therapies-idUSKCN1UX2G6